Abstract WMP1: Eligibility for Endovascular Trial Enrollment in the 6-24 Hour Time Window

    loading  Checking for direct PDF access through Ovid

Abstract

Background and Purpose: Recent completion of the DAWN trial supports the benefit of endovascular therapy in patients presenting in the 6-24 hour time window with anterior circulation large vessel occlusions. The scope and impact of these results on clinical practice remain unknown.

Methods: A retrospective review of ischemic stroke admissions to a single comprehensive stroke center was performed during the enrollment period (November 2015-February 2017) to identify patients meeting criteria for DAWN eligibility. Patients presenting beyond 6 hours were further investigated to clarify reasons for trial exclusion.

Results: Of the 2667 acute ischemic stroke patients admitted within the study period, 30% (n=792) presented within the 6-24 hour time window and 33% (890) had an NIHSS of 10 or higher. Of the 11% (n=298) patients meeting both criteria, trial exclusion occurred due to: absence of large vessel occlusion (LVO) (48%,n=143), presence of sub-occlusive, distal or posterior circulation LVO (18%, n=54), large core infarct or ASPECT < 7 (25%, n=73) or absence of clinical core mismatch (5%, n=16), mRS >1 (13%, n=38). There were 45 patients who met all DAWN criteria.

Conclusions: Of all acute ischemic stroke patients presenting to a single CSC, 1.7% of patients qualified for DAWN clinical trial enrollment. Of patients with proximal anterior circulation occlusion presenting in the 6- 24 hour time window with NIHSS of 10 or higher, 29% were eligible for treatment based on DAWN criteria. These data predict an increase in thrombectomy utilization with important implications for Comprehensive Stroke Center resource utilization and stroke systems of care.

Related Topics

    loading  Loading Related Articles